Isabelle Maronde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isabelle Maronde has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Biere
Unit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre Robert Koch Institute Berlin Germany
1 shared publication - Brunhilde Schweiger
Unit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre Robert Koch Institute Berlin Germany
1 shared publication - Djin-Ye Oh
Unit 17: Influenza and Other Respiratory Viruses, Robert Koch Institute, 13353 Berlin, Germany
1 shared publication - Doreen Staat
Unit 36, Respiratory Infections, Department of Infectious Disease Epidemiology Robert Koch Institute Berlin Germany
1 shared publication Ekkehard Schuler
HELIOS KLINIKEN GmbH Berlin Germany
1 shared publication- Janine Reiche
Unit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre Robert Koch Institute Berlin Germany
1 shared publication
Latest Publications
- Open Access
- 17 June 2026
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 20 (6) , e70274
Reduction in Respiratory Syncytial Virus (RSV)‐Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany
After introducing nirsevimab during the 2024/2025 respiratory syncytial virus (RSV) season in Germany, RSV activity in infants under 1 year dropped by 50% in primary care and 50%–70% in secondary care. Inpatients under 6 months showed the greatest reduction. RSV severity decreased with fewer RSV‐associated ICU admissions and shorter hospital stays. RSV sequence analysis identified four known polymorphisms in the nirsevimab binding site among inpatients; none associated with resistance. These findings indicate that nirsevimab effectively reduced medically attended RSV disease in infants.
- 17 June 2026
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 20 (6) , e70274
Open AccessReduction in Respiratory Syncytial Virus (RSV)‐Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany
After introducing nirsevimab during the 2024/2025 respiratory syncytial virus (RSV) season in Germany, RSV activity in infants under 1 year dropped by 50% in primary care and 50%–70% in secondary care. Inpatients under 6 months showed the greatest reduction. RSV severity decreased with fewer RSV‐associated ICU admissions and shorter hospital stays. RSV sequence analysis identified four known polymorphisms in the nirsevimab binding site among inpatients; none associated with resistance. These findings indicate that nirsevimab effectively reduced medically attended RSV disease in infants.